Lab data

PT-141 test results: how often vials pass lab testing

PT-141 is approved as Vyleesi, but the vials in these tests are research-labelled bremelanotide, and about a third of them failed.

12 November 2026 3 min read By Peptide AI Editorial policy

Of the last 153 PT-141 samples with a result in Finnrick's public lab-testing database, 100 passed and 53 failed: 65 percent of PT-141 test results were a pass. Another 5 came back incomplete and are left out. Finnrick has published 158 PT-141 tests from 47 sellers since 16 Mar 2025.

PT-141, or bremelanotide, is a melanocortin receptor agonist and one of the few compounds in our library with FDA approval. It is sold as Vyleesi, approved in 2019 for acquired, generalised hypoactive sexual desire disorder in premenopausal women. The results here are of PT-141 sold with a research-use-only label, which is not Vyleesi.

The short version

  • 65 percent of recent samples passed. 100 passed and 53 failed, of the last 153 with a result.
  • It is FDA-approved as Vyleesi, for one use in premenopausal women. A research-labelled vial is not Vyleesi.
  • A pass is a narrow result. It covers identity, purity and fill for the vial that was tested. It does not cover endotoxin, sterility or the next batch.
  • We do not name sellers. The numbers describe the market, not any one shop.

PT-141 test results in numbers

MeasurePT-141
Published tests158
Sellers with at least one test47
First and latest test16 Mar 2025 to 29 Oct 2026
Recent results counted153 (5 incomplete left out)
Passed100
Failed53
Pass rate65%
Rank by pass rate5 of 14 on our peptide test results page

Figures from Finnrick's public PT-141 page, checked on 12 November 2026. They will change as new results come in.

What counts as a pass or a fail

These figures use Finnrick's "Purity focus" standard, the one its public pages show. A sample passes when its purity is at least 99.5 percent and the amount in the vial is within 35 percent of the label. A sample that turns out to be a different molecule fails under every standard Finnrick uses. Endotoxin testing is not required under this standard, so a pass says nothing about endotoxin or sterility.

The pass rate counts passes and fails among the most recent results on Finnrick's public page, up to 200, and leaves out tests that came back incomplete. Finnrick says it sources samples from sellers and sends them to third-party labs, with HPLC as the main method. Its methodology page has the detail.

Is PT-141 FDA-approved?

Yes, as Vyleesi, for one indication in premenopausal women (see our PT-141 page). The approval covers that product. A vial of research-labelled bremelanotide is not an approved drug, whatever the molecule on its label.

About a third of research PT-141 failed

Of the last 153 PT-141 samples with a result, 100 passed and 53 failed. Melanotan II, the unapproved compound PT-141 came from, passed 62 percent (melanotan II test results). Finnrick has published 158 PT-141 tests from 47 sellers since 16 Mar 2025.

The gap between an approved drug and a research vial is the same here as for semaglutide or tesamorelin. Approval belongs to a product, and the research product has to prove itself one test at a time.

Before you buy PT-141

Bremelanotide is an approved medicine, so a prescription filled by a licensed pharmacy is the safer route. Peptide AI's prescription route through licensed telehealth is coming soon.

Before any order, three checks come first: the steps in how to vet a peptide supplier, an independent result for your own lot (how to get peptides tested), and the legal picture in is it legal to buy peptides. Products sold as research use only are not FDA-approved drugs, and a passing test does not make one safe to use.

Peptide AI is building a marketplace with two ways to buy: on a prescription through licensed telehealth, for what can legally be prescribed, or from vetted suppliers with an independent lab report you read before you order. It is not open yet. Early access is here.

Questions people ask

What percentage of PT-141 fails lab testing?

In Finnrick's public test database, 53 of the last 153 PT-141 samples with a result failed, which is 35 percent, and 100 passed. Tests that came back incomplete are left out.

Is PT-141 FDA-approved?

It is FDA-approved as Vyleesi, for one use in premenopausal women. A research-labelled vial is not Vyleesi.

Does a passing lab test mean PT-141 is safe?

No. A pass means the sample matched its label on identity, purity and fill under one standard. It does not cover endotoxin, sterility, other vials, or whether PT-141 is safe or does anything in people.

Is research PT-141 the same as Vyleesi?

No. Vyleesi is the approved product. A research-labelled vial uses the same molecule name, and 53 of the last 153 tested samples failed.

Sources

  1. Methodology, Finnrick, accessed 12 November 2026
  2. PT-141 product page and public test history, Finnrick, accessed 12 November 2026
Free on iOS and Android

Log it once. See it all on one timeline.

Doses, food, training, labs, sleep and scans on one timeline. On iOS and Android.

The PeptideAI protocol screen with a weekly GLP-1 dose on it.